TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04149821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: -Co-administered on days 1 and 2 (dose split over days 1 and 2), 8, 15 of cycle 1 then on day 1 for subsequent cycles 2-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: -Co-administered on days 1 and 2 (dose split over days 1 and 2), 8, 15 of cycle 1 then on day 1 for subsequent cycles 2-6
Study: NCT06696469

Intervention type: DIAGNOSTIC_TEST
Intervention: Feasibility and reliability of using BeCureTM Virtual Reality in the evaluation of upper extremity motor functions in stroke patients
Description: The applicability and reliability of virtual reality systems are important factors to consider. Based on this, this study aimed to investigate the feasibility of using BeCureTM virtual reality in the evaluation of upper extremity functions after stroke.The feasibility of using BeCureTM virtual reality in stroke patients will be determined according to the System Usability Scale (SUS) score.The safety of the use of BeCureTM virtual reality in stroke patients will be assessed with a patient feedback questionnaire. The relationship between the use of BeCureTM virtual reality and cognitive functions in stroke patients will be determined by the Montreal Cognitive Assessment Scale and Mini Mental State Examination.It was aimed to examine the effects of demographic characteristics, accompanying cognitive disorders and upper extremity motor disorders that may affect the evaluation and response to treatment on virtual reality applications.
Study: NCT06701851

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voluntary and involuntary conditions
Description: An task fMRI/EEG acquisition during the prodromal phase preceding the episode of abnormal movements.~A task fMRI/EEG acquisition the episode of abnormal movements A task fMRI/EEG acquisition when the subject voluntary mimics the sequence of events (prdrosomal phase + episode of dyskinesia)
Study: NCT06700629

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Distal Penile Hypospadias (Disorder)
Description: Three operations which are Tubularized incised plate urethroplasty (TIP), Mathieu and meatal advancement and glanuplasty (MAGPI).~A three experienced operators with number of operations done by each one more than one hundred operation in the last year.~The operators will be fixed for each surgical technique as follows:~1. Doctor (A) for Matheiu. ( 35 operations)~2. Doctor (M) for MAGPI. ( 35 operations)~3. Doctor (S) for TIP ( 35 operations). Tubularized incised plate urethroplasty:(3,6) Indication: for distal penile hypospadias with or without penile curvature with any width of the uretheral plate and also for any type of distal hypospadias associated with curvature.~Key steps for this operation are as follows:~Glans retraction using stay suture 4-0 or 5-0 silk. Uretheral catheter pass through hypospadic meatus to bladder. Parallel longitudenal incision is done 1-2mm proximal to hypospadic meatus. A circumferential incision is made 2-3 mm below coronal sulcus dorsally
Study: NCT06698614

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI imaging of the kidney and heart with an intravenous infusion of manganese dipyridoxl diphosphate (Mangafodipir, MnDPDP).

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI imaging of the kidney and heart with an intravenous infusion of manganese dipyridoxl diphosphate (Mangafodipir, MnDPDP).

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI imaging of the kidney and heart with an intravenous infusion of manganese dipyridoxl diphosphate (Mangafodipir, MnDPDP).

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI imaging of the kidney and heart with an intravenous infusion of manganese dipyridoxl diphosphate (Mangafodipir, MnDPDP).

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI imaging of the kidney and heart with an intravenous infusion of manganese dipyridoxl diphosphate (Mangafodipir, MnDPDP).

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI imaging of the kidney and heart with an intravenous infusion of manganese dipyridoxl diphosphate (Mangafodipir, MnDPDP).

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood tests
Description: full blood count, urea and electrolytes, liver function test, CRP, biomarkers for endothelial function, storage of serum and plasma for future analyses.
Study: NCT06048744

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: external oblique intercostal block
Description: U S guided external oblique intercostal block after induction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spine block
Description: US guided erector spine block after induction
Study: NCT05888220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: warm salt water bath
Description: Warm water and warm salt water bath were applied to the hands and feet of the patients. It is a non-pharmacological intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: warm salt water bath
Description: Warm water and warm salt water bath were applied to the hands and feet of the patients. It is a non-pharmacological intervention
Study: NCT06698614

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood tests
Description: full blood count, urea and electrolytes, liver function test, CRP, biomarkers for endothelial function, storage of serum and plasma for future analyses.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood tests
Description: full blood count, urea and electrolytes, liver function test, CRP, biomarkers for endothelial function, storage of serum and plasma for future analyses.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood tests
Description: full blood count, urea and electrolytes, liver function test, CRP, biomarkers for endothelial function, storage of serum and plasma for future analyses.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood tests
Description: full blood count, urea and electrolytes, liver function test, CRP, biomarkers for endothelial function, storage of serum and plasma for future analyses.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood tests
Description: full blood count, urea and electrolytes, liver function test, CRP, biomarkers for endothelial function, storage of serum and plasma for future analyses.
Study: NCT04534530

Intervention type: OTHER
Intervention: Systematic screening for ischemic heart disease in type 2 diabetic patients
Description: Systematic screening for ischemic heart disease in type 2 diabetic patients at very high cardiovascular risk, without known coronary heart disease.

Intervention type: OTHER
Intervention: Systematic screening for ischemic heart disease in type 2 diabetic patients
Description: Systematic screening for ischemic heart disease in type 2 diabetic patients at very high cardiovascular risk, without known coronary heart disease.
Study: NCT04691362

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid Oral Product
Description: Oral administration of 2 grammes tranexamic acid 2 hours before skin incision and 2 grammes oral tranexamic acid 4 hours after first administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: Intravenous administration of 1 gramme tranexamic acid 30 minutes before skin incision and 1 gramme intravenous tranexamic acid 4 hours after first administration
Study: NCT06303804

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational videos
Description: Participants will be delivered a link to complete demographic information and the initial assessment. Upon completing the (initial) pre-test knowledge assessment, participants will be sent links to the three educational videos staggered across 7 days. Educational videos will determine gaps in knowledge related to opioid use and overdose based on questionnaire responses. Upon the completion of the 7 days, participants will be sent a link to the (final) post-test knowledge assessment to complete.
Study: NCT05277883

Intervention type: RADIATION
Intervention: CT scan
Description: CT of the lower limb
Study: NCT02028897

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional embryo culture

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enclosed embryo culture
Study: NCT05379413

Intervention type: DRUG
Intervention: Botulinum toxin type A
Description: Botulinum neurotoxin (BoNT) Type A injection with either OnaBoNT-A, AboBoNT-A, IncoBoNT-A

Intervention type: DRUG
Intervention: Botulinum toxin type A
Description: Botulinum neurotoxin (BoNT) Type A injection with either OnaBoNT-A, AboBoNT-A, IncoBoNT-A
Study: NCT04578873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QPX7831
Description: capsule
Study: NCT06698614

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine tests
Description: Urine protein, Urine creatinine

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine tests
Description: Urine protein, Urine creatinine

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine tests
Description: Urine protein, Urine creatinine

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine tests
Description: Urine protein, Urine creatinine

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine tests
Description: Urine protein, Urine creatinine

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine tests
Description: Urine protein, Urine creatinine
Study: NCT04578873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QPX7831
Description: capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo comparator
Description: oral matched placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo comparator
Description: oral matched placebo capsule
Study: NCT05531214

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Care Coordination Team
Description: The intervention group will be patients whose primary care clinicians will be receiving guidance and recommendations from the multidisciplinary team consisting of cardiologists, nephrologists, and specialty pharmacists.
Study: NCT05853094

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ileostomy
Description: Protective loop ileostomy after low anterior resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transverse colostomy
Description: Protective loop transverse colostomy after low anterior resection
Study: NCT05861115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chang Gung Ventricular Systolic Dysfunction Screening Software
Description: This software is suitable for 12-lead ECG signals of adults over 20 years old, and assists doctors in screening patients for left ventricular systolic dysfunction.
Study: NCT03059173

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myo-Inositol + Levomefolic acid
Description: Dietary supplement Gynositol® MTHF containing myo-inositol (4 g) and Levomefolic acid on glucosamine salts(0.736 mg) in a same bags Supplementation started on average one month before treatment with Clomiphene citrate and continued throughout cycles of Clomiphene citrate (maximum 9 cycles). Treatment will be delivered during ultrasound visit at D12 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate
Description: Clomiphene citrate 50 mg. taking D2 to D6 of each cycle (maximum 9 cycles). Treatment will be delivered during ultrasound visit at D12 of each cycle and the dose will be increased if necessary.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clomiphene Citrate
Description: Clomiphene citrate 50 mg. taking D2 to D6 of each cycle (maximum 9 cycles). Treatment will be delivered during ultrasound visit at D12 of each cycle and the dose will be increased if necessary.
Study: NCT06698614

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular analysis
Description: 24 hour blood pressure, arterial stiffness

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular analysis
Description: 24 hour blood pressure, arterial stiffness

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular analysis
Description: 24 hour blood pressure, arterial stiffness

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular analysis
Description: 24 hour blood pressure, arterial stiffness

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular analysis
Description: 24 hour blood pressure, arterial stiffness

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular analysis
Description: 24 hour blood pressure, arterial stiffness
Study: NCT06702202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mixture of local anesthetics
Description: Marcaine® (bupivacaine HCl) 0,5% and Xylocaine® (Lidocaine HCL) 2% = 2:1 Given in Femoropopliteal block group (Group F)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% hyperbaric bupivacaine
Description: Given in Subarachnoid block group (Group S)
Study: NCT06701266

Intervention type: DEVICE
Intervention: Point of Care Test
Description: PoCT as a chairside test, ELISA as a gold standard
Study: NCT06700499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120 300mg Q2W (JAK inhibitor users need to double the initial dose)
Description: AK120 300mg Q2W SC until week 14(JAK inhibitor users need to receive a first dose of 600mg SC)
Study: NCT06700564

Intervention type: OTHER
Intervention: PET scan of FDG
Description: The enrolled patients will undergo PET examination, and the radiation dose generated during the examination will not cause physiological damage to the patients
Study: NCT03059173

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: a placebo containing only 0.736 mg of 5-MTHF, glucosamine salts
Study: NCT04093934

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation
Description: Children will receive fortnightly sessions of psychosocial stimulation and nutritional support for one year during the study period.
Study: NCT05828095

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-6160, 2 mg
Description: ID EP at month 0,1,3 and 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-6160, 2 mg
Description: ID EP at month 0,1,3 and 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trimer-4571 / 100 mcg 3M-052-AF (5 mcg) + Alum (500 mcg)
Description: IM at month 3 and 6
Study: NCT06700408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dachaihu Decoction combined Erzhiwan with variation
Description: Chinese medicine granules
Study: NCT05015153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR)
Description: 20 sessions of PR in respiratory rehabilitation centre will be performed over a period of 3 months
Study: NCT06700408

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo granules
Description: Placebo granules
Study: NCT06421233

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage
Description: Endorphin massage will be given for 15 minutes every 2 hours.
Study: NCT04964089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSI-301
Description: Intravitreal Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Intravitreal Injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
Study: NCT06703463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1167
Description: Administered via oral capsule per dosing regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1167
Description: Administered via oral capsule per dosing regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: Diltiazem hydrochloride administered at a dose of 240 mg QD via oral capsules.
Study: NCT06702995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW5004
Description: Oral continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW5004
Description: Oral continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW5004
Description: Oral continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: enzalutamide 160 mg (four 40 mg capsules) orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: enzalutamide 160 mg (four 40 mg capsules) orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: enzalutamide 160 mg (four 40 mg capsules) orally once daily
Study: NCT05689034

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azvudine
Description: Azvudine po. 5mg daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo po. 5 tablets daily for 7 days
Study: NCT04925479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib Pediatric formulation group
Description: Asciminib Pediatric formulation group: Mini-tablets will be supplied as size 0 capsules containing 1 mg mini-tablets, taken orally:~10 mg (10x 1 mg tablets in capsule) 15 mg (15x 1 mg tablets in capsule) 20 mg (20x 1 mg tablets in capsule) 30 mg (30x 1 mg tablets in capsule)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib Adult formulation group
Description: Asciminib Adult formulation group:~40 mg tablets BID, taken orally. 20 mg tablets BID, taken orally.
Study: NCT05756413

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-determination theory
Description: SDT is relatively unique among theories of motivation due to its focus on the quality, rather than the quantity, of motivation. Central to SDT is the distinction between selfdetermined or autonomous and non-self-determined or controlled forms of motivation. These types of motivation differ from one another based on the degree to which actions are (or are not) fully self-endorsed by the individual. Autonomous motivation reflects freely chosen and fully or whole-heartedly self-endorsed reasons for engaging in a behavior, such as because it is important and because it is enjoyable. In contrast, controlled motivation reflects reasons for acting that are not self-endorsed because one is pressured into doing them because of internal pressure, such as this is something I should do, even though I don't really want to, or because of environmental contingencies because I have to; it is required that I do this.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-determination theory
Description: SDT is relatively unique among theories of motivation due to its focus on the quality, rather than the quantity, of motivation. Central to SDT is the distinction between selfdetermined or autonomous and non-self-determined or controlled forms of motivation. These types of motivation differ from one another based on the degree to which actions are (or are not) fully self-endorsed by the individual. Autonomous motivation reflects freely chosen and fully or whole-heartedly self-endorsed reasons for engaging in a behavior, such as because it is important and because it is enjoyable. In contrast, controlled motivation reflects reasons for acting that are not self-endorsed because one is pressured into doing them because of internal pressure, such as this is something I should do, even though I don't really want to, or because of environmental contingencies because I have to; it is required that I do this.
Study: NCT05290272

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ViFIVE Digital Care Progrma
Description: ViFive DCP (Digital Care Program) is a highly structured, protocolized, and individually tailored intervention consisting of personalized exercise therapy modules. ViFive DCP is delivered by a physical therapy team consisting of DPTs and a personal coach. The DCP consists of ten modules and its advancement will be determined by each patient's progress after the treatment team's review every week.
Study: NCT06137729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07899895
Description: Participants will receive oral ascending doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo.
Study: NCT06172933

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Move with Meaning
Description: Participants will engage in twice weekly text message sessions, will listen to a weekly audio session, and will work towards a physical activity goal each week, for a total of eight weeks.
Study: NCT05684497

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LBPSP in Pregnancy
Description: LBPSP is a 50-minute interactive presentation as face to face program according to Pender's Health Promotion Model Parameters.
Study: NCT05926544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard implementation webinar and online training
Description: The one-hour webinar (either live or pre-recorded) will include updated information about the COVID-19 virus, variant nomenclature, booster eligibility, mechanisms of action, and outcomes.~The 30-minute online training addresses how to communicate about COVID-19 vaccinations, presents a 5-step process for initiating conversations, includes example verbiage about how to address specific concerns, and has example videos that show how to implement the 5-step process with vaccine hesitant patients.
Study: NCT05655182

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PIV5-vectored RSV Vaccine (BLB-201) Low Dose
Description: BLB201 10\^6 PFU
Study: NCT05926544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual facilitation
Description: This intervention involves a 30-minute virtual facilitation site visit and 8 30-minute virtual facilitator coaching sessions. The virtual site visit over Zoom will establish the personnel and workflows at each pharmacy and allow the facilitator to establish rapport. Weekly Zoom calls will allow the virtual facilitator to work with a participant to review overall implementation challenges associated with approaching patients, delivering the intervention, and documenting results. Lastly, either the facilitator or the participant can request and schedule a Zoom call to go over any pressing implementation issue in need of rapid attention (e.g., technical difficulties with the website).
Study: NCT04961112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cranial Electrotherapy Stimulation
Description: Participants will receive cranial electrotherapy stimulation stimulation on one of two separate visits (within-subjects).